43 results about "Vein occlusion" patented technology

Systems and methods are described providing for the use of ultrasound energy to effect the dislodging of one or more blood clots inside blood vessels. Such clots can include those inside retinal vessels, especially in patients with central retinal vein occlusion. Embodiments of the present disclosure may be used for any retinal arterial or venous occlusion. In exemplary embodiments, a small probe can be inserted into the eye of a patient and placed over the retinal vessels. Acoustic streaming created by the probe can be directed to an area or region including targeted blood vessels, resulting in increased flow in one or more retinal veins and facilitating or effecting mechanical dislodging of one or more blood clots in the targets blood vessels. Exemplary embodiments can utilize ultrasonic energy produced at a frequency of approximately 44 MHz to 46 MHz with pulse repetition frequencies of approximately 100 Hz to 100 kHz.

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

A device for treatment of venous congestion provides for subcutaneous introduction of anticoagulant through an incision positioned within a collection shell for withdrawal of an effused material. A widened delivery tip provides dispersal of the anticoagulant and may be agitated to disrupt clot formation.

This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.

Provided is a medicine for preventing or treating an ophthalmic disease associated with enhanced intraocular neovascularization and / or intraocular vascular permeability. The present inventors have made studies on medicines for preventing or treating ophthalmic diseases associated with enhanced intraocular neovascularization and / or intraocular vascular permeability. As a result, it is confirmed that a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor has an activity to prevent intraocular neovascularization and an activity to prevent intraocular vascular permeability, and the present invention is accomplished. A compound according to the present invention, which is a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor or a pharmaceutically acceptable salt thereof has an activity to prevent intraocular neovascularization and intraocular vascular permeability, and can be used as a prophylactic and / or therapeutic agent for exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, neovascular glaucoma or the like.

The Yimaikang dispersion tablet consists of fleabane extractum and medicine carrier. Its recipe includes fleabane extractum, lactose, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvidon, steviosin, alcohol, fine silica gel powder and magnesium stearate. The dispersion tablet can disintegrate completely in 3 min to reach homogeneous dispersive state and its effective component andrographolide has dissolving rate reaching 60 % in 10 min. It is used in treating ischemic cerebral vascular diseases, cerebral hemorrhage sequela, vein obstruction, etc. and has fast acting, good taste and convenient taking.

The invention discloses a pen-type venous occlusion device. The device comprises a scanning probe, a casing, a controller, a liquid crystal screen, a battery pack and a control switch, wherein the scanning probe is arranged at the front end of the casing, a pressure sensor is arranged on the surface of the scanning probe, and an ultrasonic transducer is arranged in the scanning probe; the liquid crystal screen is arranged on the outer surface of the upper part of the casing, and the control switch is arranged at the top end of the casing; the pressure sensor, the ultrasonic transducer, the liquid crystal screen and the control switch are respectively connected with controller which is arranged inside the casing; the battery pack is arranged in the casing and connected with the controller. The pen-type venous occlusion device is novel in structure and convenient to use, can be used for observing the situation of blood vessels and preventing angiectopia of neck, oxter or other parts during PICC or port-cath cathetering, can be used when PICC or port-cath ectopia is treated by a finger-press method, can be used for assisting a doctor to observe the situation of venous occlusion and pressing occluded veins by proper pressure according to requirement, so that ectopic catheter or port-cath is restored to a normal position.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

A method and device for reducing the concentration of VEGF in the eye. This device is used for measuring the concentration of VEGF by taking the liquid in the vitreous cavity after vitrectomy; Reduce the concentration of VEGF, prevent and treat a series of intraocular neovascular diseases secondary to various diseases such as diabetic retinopathy and retinal vein occlusion. The device can indwell the eyeball for a long time during the treatment of eye diseases, and take it out after all the intraocular treatments are finished.

The invention relates to a puerarin sodium phosphate injection and a preparation method thereof. The preparation consists of sodium puerarin phosphate, antiseptic, isotonic regulator, pH regulator, antioxidant, local analgesic and water for injection. The addition of antioxidants can improve the stability of the preparation, and the addition of local analgesics can reduce the pain of patients without affecting the main drug. The preparation process of the preparation mainly includes weighing, dissolving, pyrogen adsorption by activated carbon, filtering, constant volume, terminal filtering, sub-packaging and sealing and capping. The preparation is used for auxiliary treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, sudden deafness and ischemic cerebrovascular disease, etc. The preparation has stable quality, definite curative effect and is favorable for patients to accept.